Stock Traders Purchase High Volume of Call Options on Accelerate Diagnostics (AXDX)

Accelerate Diagnostics Inc (NASDAQ:AXDX) saw some unusual options trading on Monday. Investors bought 3,074 call options on the company. This represents an increase of 713% compared to the typical volume of 378 call options.

Shares of Accelerate Diagnostics (NASDAQ AXDX) traded up $0.35 on Wednesday, hitting $23.25. The stock had a trading volume of 415,977 shares, compared to its average volume of 283,132. The stock has a market cap of $1,290.00, a PE ratio of -19.38 and a beta of 2.19. Accelerate Diagnostics has a fifty-two week low of $16.75 and a fifty-two week high of $30.45.

In other news, Director Jack W. Schuler bought 5,500 shares of the stock in a transaction that occurred on Friday, November 17th. The stock was bought at an average cost of $22.00 per share, for a total transaction of $121,000.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 50.00% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of Accelerate Diagnostics by 1.1% in the 4th quarter. BlackRock Inc. now owns 1,683,028 shares of the medical research company’s stock valued at $44,095,000 after buying an additional 17,848 shares during the period. Vanguard Group Inc. boosted its stake in shares of Accelerate Diagnostics by 6.7% in the 2nd quarter. Vanguard Group Inc. now owns 1,237,174 shares of the medical research company’s stock valued at $33,837,000 after buying an additional 77,753 shares during the period. ArrowMark Colorado Holdings LLC boosted its stake in shares of Accelerate Diagnostics by 8.6% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 934,252 shares of the medical research company’s stock valued at $24,477,000 after buying an additional 73,770 shares during the period. Next Century Growth Investors LLC boosted its stake in shares of Accelerate Diagnostics by 30.5% in the 4th quarter. Next Century Growth Investors LLC now owns 660,020 shares of the medical research company’s stock valued at $17,292,000 after buying an additional 154,387 shares during the period. Finally, Kornitzer Capital Management Inc. KS boosted its stake in shares of Accelerate Diagnostics by 37.3% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 530,219 shares of the medical research company’s stock valued at $11,903,000 after buying an additional 144,055 shares during the period. Institutional investors and hedge funds own 47.56% of the company’s stock.

A number of equities analysts recently commented on AXDX shares. BTIG Research cut Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a report on Wednesday, December 13th. They noted that the move was a valuation call. Zacks Investment Research cut Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Monday, January 15th. ValuEngine upgraded Accelerate Diagnostics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, BidaskClub cut Accelerate Diagnostics from a “buy” rating to a “hold” rating in a report on Tuesday. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $33.00.

TRADEMARK VIOLATION WARNING: This report was originally published by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/02/14/stock-traders-purchase-high-volume-of-call-options-on-accelerate-diagnostics-axdx.html.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply